This Phase 2 trial is a 52-week study evaluating the safety and efficacy of ublituximab at accelerated infusion times as fast as one hour. Source: BioSpace
Sometimes the biggest are also the best. That's the case for biotherapeutics stocks. Source: BioSpace
Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace
The European Medicines Agency released a draft revised guideline for safety and efficacy follow-up of advanced therapy medicinal products, including gene therapies, cell therapies and tissue engineering. Source: Drug Industry…
Teikoku Pharma reached an agreement with 22 state attorneys general to end a lawsuit accusing the drugmaker of obstructing generic competition. Source: Drug Industry Daily
The FDA is working with providers, manufacturers and distributors to head off potential saline shortages during flu season, FDA Commissioner Scott Gottlieb said Thursday. Source: Drug Industry Daily
Three supermarket chains sued more than 20 generic drug manufacturers, including Actavis, Apotex, Mylan, Teva and Sandoz, alleging they engaged in a conspiracy to set prices. Source: Drug Industry Daily
Sluggish growth is the main driver for the decision.. Source: BioSpace
The company plans to initiate a Phase 2 clinical trial this year with AVR-RD-01 in Fabry disease. Source: BioSpace
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board. Source: BioSpace